Skip to main content
Canna~Fangled Abstracts

Cannabis in the management of PTSD: a systematic review

By May 14, 2021June 30th, 2021No Comments

Review
. 2021 May 13;8(3):414-434.

doi: 10.3934/Neuroscience.2021022. eCollection 2021.

Yasir Rehman 1 2 3, Amreen Saini 4, Sarina Huang 5, Emma Sood 4, Ravneet Gill 4, Sezgi Yanikomeroglu 5
Affiliations 

Abstract

Introduction: Existing reviews exploring cannabis effectiveness have numerous limitations including narrow search strategies. We systematically explored cannabis effects on PTSD symptoms, quality of life (QOL), and return to work (RTW). We also investigated harm outcomes such as adverse effects and dropouts due to adverse effects, inefficacy, and all-cause dropout rates.

Methods: Our search in MEDLINE, EMBASE, PsycInfo, CINAHL, Web of Science, CENTRAL, and PubMed databases, yielded 1 eligible RCT and 10 observational studies (n = 4672). Risk of bias (RoB) was assessed with the Cochrane risk of bias tool and ROBINS-I.

Results: Evidence from the included studies was mainly based on non-randomized studies with no comparators. Results from unpooled, high RoB studies showed that cannabis was associated with a reduction in overall PTSD symptoms and improved QOL. Dry mouth, headaches, and psychoactive effects such as agitation and euphoria were the commonly reported adverse effects. In most studies, cannabis was well tolerated, but small proportions of patients experienced a worsening of PTSD symptoms.

Conclusion: Evidence in the current study primarily stems from low quality and high RoB observational studies. Further RCTs investigating cannabis effects on PTSD treatment should be conducted with larger sample sizes and explore a broader range of patient-important outcomes.

 

Keywords: PTSD, THC, cannabinoid, cannabis, functional improvement, meta-analysis, nabilone, symptoms reduction, systematic review

Conflict of interest statement

Conflict of interest: The authors declare no conflict of interest.

Figures

Figure 1.

References

    1. Stein DJ, McLaughlin KA, Koenen KC, et al. DSM-5 and ICD-11 definitions of posttraumatic stress disorder: investigating “narrow” and “broad” approaches. Depress Anxiety. 2014;31:494–505. – PMC – PubMed
    1. Pai A, Suris AM, North CS. Posttraumatic Stress Disorder in the DSM-5: Controversy, Change, and Conceptual Considerations. Behav Sci (Basel) 2017;7:7. – PMC – PubMed
    1. Richardson LK, Frueh BC, Acierno R. Prevalence estimates of combat-related post-traumatic stress disorder: critical review. Aust N Z J Psychiatry. 2010;44:4–19. – PMC – PubMed
    1. Rehman Y, Sadeghirad B, Guyatt GH, et al. Management of post-traumatic stress disorder: A protocol for a multiple treatment comparison meta-analysis of randomized controlled trials. Medicine. 2019;98:e17064. – PMC – PubMed
    1. Acheson DT, Gresack JE, Risbrough VB. Hippocampal dysfunction effects on context memory: possible etiology for posttraumatic stress disorder. Neuropharmacology. 2012;62:674–685. – PMC – PubMed

Publication types

Leave a Reply